News
NTRA
167.26
-1.24%
-2.10
Insider Sale: Director at $NTRA (NTRA) Sells 2,100 Shares
Barchart · 1d ago
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Barchart · 2d ago
SPDR S&P Biotech ETF Experiences Big Outflow
NASDAQ · 2d ago
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
The Motley Fool · 2d ago
Goldman’s Hedge Fund VIP List: AMZN, VST, CRM, BABA, and more
Seeking Alpha · 3d ago
Trump Media saw the largest increase in short interest in October
Seeking Alpha · 3d ago
JPMorgan’s ‘Analyst Focus List’ – growth, income, value, short ideas
Seeking Alpha · 4d ago
NATERA INC <NTRA.O>: UBS RAISES TARGET PRICE TO $209 FROM $145
Reuters · 4d ago
Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%
Simply Wall St · 4d ago
U.S. RESEARCH ROUNDUP-Equifax, Microstrategy, Netflix
Reuters · 4d ago
Analyst Expectations For Natera's Future
Benzinga · 5d ago
Natera Is Maintained at Overweight by Piper Sandler
Dow Jones · 5d ago
Natera Price Target Raised to $200.00/Share From $150.00 by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Maintains Overweight on Natera, Raises Price Target to $200
Benzinga · 5d ago
First Week of July 2025 Options Trading For Natera (NTRA)
NASDAQ · 5d ago
NATERA INC <NTRA.O>: PIPER SANDLER RAISES TARGET PRICE TO $200 FROM $150
Reuters · 5d ago
Weekly Report: what happened at NTRA last week (1111-1115)?
Weekly Report · 5d ago
Life sciences stocks viewed positively at TD Cowen despite post-election weakness
Seeking Alpha · 11/15 20:55
Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158
Simply Wall St · 11/15 11:43
Druckenmiller's Duquesne closes some media holdings, loads into regional banks, among Q3 trades
Seeking Alpha · 11/14 21:24
More
Webull provides a variety of real-time NTRA stock news. You can receive the latest news about Natera Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRA
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.